Position in SABS
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$176,139
New position
Shares Held
45,164
first reported quarter
Ownership
0.050%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#45
of 86 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 19%
Shared 0%
None 81%
Position in Biotechnology
Healthcare · as of Jun 30, 2026RHUMBLINE ADVISERS holds $1,404,724,682 across 329 Biotechnology names. SABS ranks #253 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
396,380 | $196,893,837 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
157,794 | $98,390,870 | |
| 3 | MRNA |
Moderna, Inc.
|
809,853 | $56,714,005 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
165,579 | $49,844,246 | |
| 5 | INCY |
Incyte Corp
|
428,533 | $48,578,500 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
226,008 | $42,326,778 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
1,178,789 | $41,717,342 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
163,018 | $39,282,447 |
All Filings in SABS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $176,139 | 45,164 | Shares | Sole | 2026-08-12 | |
| No filing history on record for this holder in this stock. | ||||||